Mouse modeling in oncologic preclinical and translational research.
Through scientific and technological advancements, our ability to manipulate the mouse genome has allowed us to evaluate the effect of specific genetic alterations on in vivo tumorigenesis. This has allowed and will allow us to define molecular pathways describing the processes of tumor initiation, invasion, and progression to metastatic disease. Additionally, these models may serve as an excellent platform for the identification of novel molecular targets for therapy as well as to evaluate the efficacy of targeted therapies. Ultimately this will translate from preclinical mouse model trials to the development of clinical trials and protocols for cancer patients. Here we review the usefulness of mouse modeling in oncologic translational research.
Carver
Brett S
BS
Cancer Biology and Genetics Program and Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Pandolfi
Pier P
PP
D000818:Animals; D004195:Disease Models, Animal; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000639:trends; D017353:Gene Deletion; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D039902:Multipotent Stem Cells / Q000378:metabolism; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology*; D051058:Oncogene Protein v-akt / Q000502:physiology; D051059:PTEN Phosphohydrolase / Q000235:genetics; D011471:Prostatic Neoplasms / Q000235:genetics; D023041:Xenograft Model Antitumor Assays
D051058:Oncogene Protein v-akt; D051059:PTEN Phosphohydrolase; C487757:Pten protein, mouse